BRAF and brain stem glioma: For example, adults with recurrent brainstem glioma harboring a BRAF V600E mutation may qualify for the recently initiated NCI-MATCH study, which includes an arm for patients with tumors with BRAF V600E mutation to receive a combination of dabrafenib and trametinib.